Humanigen CEO to Present at NobleCon14, BIO CEO Investor Conferences


BRISBANE, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments, announced today that Cameron Durrant, M.D., chairman and CEO, will present a company overview at two upcoming investor conferences.

Dr. Durrant will outline Humanigen’s continuing transformation into a cutting-edge science biotechnology company by repositioning and developing its proprietary monoclonal antibodies, including lead asset lenzilumab for the potential prevention of neurotoxicity associated with chimeric antigen receptor T-cell (CAR-T) therapy.

Details of the presentations follow:

In addition, senior management will hold one-on-one meetings at the conferences. To schedule a meeting, please use the investor contacts below.

About Humanigen 

Humanigen, Inc. is a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments. Derived from the company’s Humaneered® platform, lenzilumab and ifabotuzumab are lead compounds in the portfolio of monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets granulocyte-macrophage colony-stimulating factor (GM-CSF), is in development as a potential medicine to make chimeric antigen receptor T-cell (CAR-T) therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab, which targets Ephrin type-A receptor 3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers. For more information, visit www.humanigen.com.

CONTACT:

Investors:
Cameron Durrant
650-243-3181
cdurrant@humanigen.com

Mike Cole
O: 949-259-4988
C: 949-444-1341
mike.cole@mzgroup.us

Media:
media@humanigen.com